Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansionMiguel Martínez-Cava2026-10-01T07:00:04+02:00October 1, 2026|Read More
mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access WorldwideMiguel Martínez-Cava2026-09-18T07:16:55+02:00September 18, 2026|Read More
mAbxience and Amneal Announce FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®Miguel Martínez-Cava2025-12-22T22:02:19+01:00December 22, 2025|Read More
mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar developmentMiguel Martínez-Cava2025-12-17T10:19:49+01:00December 4, 2025|Read More
mAbxience announces European Commission approval of denosumab biosimilarsClara Prieto2025-07-02T15:00:56+02:00July 2, 2025|Read More
mAbxience and Corapharm Announce Strategic Licensing Agreement for Biosimilar Candidate in Southeast EuropeMiguel Martínez-Cava2025-07-02T12:29:30+02:00June 2, 2025|Read More
mAbxience and Abiogen Pharma Announce Strategic Licensing Agreement for Biosimilar Candidate in ItalyMiguel Martínez-Cava2025-07-02T12:28:58+02:00May 26, 2025|Read More
mAbxience and Egis Enter Strategic License Agreement for Biosimilar Candidates in Key Central and Eastern European MarketsMiguel Martínez-Cava2024-11-12T08:59:05+01:00November 12, 2024|Read More
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar CandidateMiguel Martínez-Cava2024-10-03T14:33:04+02:00October 3, 2024|Read More
mAbxience Appoints Jurgen Van Broeck as New CEOMiguel Martínez-Cava2024-05-09T09:42:26+02:00May 9, 2024|Read More
